Evidence map›Paper›PMID 39100283›Full record

ArticleACS omega2024

Serum

Akeem Sanni, Md Abdul Hakim, Mona Goli, Moyinoluwa Adeniyi, Farid Talih, Bartolo Lanuzza, Firas Kobeissy, Giuseppe Plazzi, Monica Moresco, Stefania Mondello and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. PredictiveACS omega · 2026
    Article
  2. SerumJournal of proteome research · 2025
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Akeem SanniChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas 79409, United States.ORCID https://orcid.org/0000-0002-1250-7293
Md Abdul HakimChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas 79409, United States.
Mona GoliChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas 79409, United States.
Moyinoluwa AdeniyiChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas 79409, United States.
Farid TalihDepartment of Psychiatry, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.
Bartolo LanuzzaSleep Research Centre, Department of Neurology IC, Oasi Research Institute-IRCCS, Troina 94018, Italy.
Firas KobeissyDepartment of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut 1107 2020, Lebanon.
Giuseppe PlazziIRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna 40138, Italy.
Monica MorescoIRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna 40138, Italy.
Stefania MondelloDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina 98122, Italy.
Raffaele FerriSleep Research Centre, Department of Neurology IC, Oasi Research Institute-IRCCS, Troina 94018, Italy.
Yehia MechrefChemistry and Biochemistry Department, Texas Tech University, Lubbock, Texas 79409, United States.ORCID https://orcid.org/0000-0002-6661-6073

Funding

Sensitive and Quantitative MS-bases Glycomic Mapping PlatformR01GM112490 · NIGMS · TEXAS TECH UNIVERSITY · PI MECHREF, YEHIA · 2014 to 2024
$3.2M
Quantitative Characterization of Glycopeptide IsomersR01GM130091 · NIGMS · TEXAS TECH UNIVERSITY · PI Yehia Mechref · 2019 to 2026
$2.5M
NIGMS NIH HHS R01 GM112490NIGMS NIH HHS R01 GM130091
6 · The paper itself

Abstract

The neurological condition known as narcolepsy type 1 (NT1) is an uncommon condition marked by extreme daytime sleepiness, cataplexy, sleep paralysis, hallucinations, disrupted nocturnal sleep, and low or undetectable levels of orexin in the CSF fluid. NT1 has been hypothesized to be an immunological disorder; its treatment is currently only symptomatic, and misdiagnosis is not uncommon. This study compares the

Identifiers

PMID39100283
PMCPMC11292663

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.